Cargando…

Novel cucurmosin‐based immunotoxin targeting programmed cell death 1‐ligand 1 with high potency against human tumor in vitro and in vivo

Immunotoxins are Ab‐cytotoxin chimeric molecules with mighty cytotoxicity. Programmed cell death 1‐ligand 1 (PD‐L1), is a transmembrane protein expressed mainly in inflammatory tumor tissues and plays a pivotal role in immune escape and tumor progression. Although PD‐L1 immune checkpoint therapy has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Caiyun, Xiong, Jiani, Lan, Yinxiang, Wu, Jingyu, Wang, Chengyan, Huang, Zhihong, Lin, Jizhen, Xie, Jieming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469839/ https://www.ncbi.nlm.nih.gov/pubmed/32589330 http://dx.doi.org/10.1111/cas.14549

Ejemplares similares

Novel EGFR-bispecific recombinant immunotoxin based on cucurmosin shows potent anti-tumor efficiency in vitro
por: Zhang, Caiyun, et al.
Publicado: (2021)

Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro
por: Deng, Cuimin, et al.
Publicado: (2017)

Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
por: Flavell, D. J., et al.
Publicado: (1997)

Attenuated T Cell Responses to a High-Potency Ligand In Vivo
por: Corse, Emily, et al.
Publicado: (2010)

Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
por: Andersson, Y, et al.
Publicado: (2009)

In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin
por: Hosseininejad-Chafi, Mohammad, et al.
Publicado: (2022)

Immunotoxins: experimental design
por: Dall, P, et al.
Publicado: (2001)

Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013)

Countering immunotoxin immunogenicity
por: Flavell, David J
Publicado: (2016)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Targeting malignant B cells with an immunotoxin against ROR1
por: Baskar, Sivasubramanian, et al.
Publicado: (2012)

The predictive role of soluble programmed death ligand 1 in digestive system cancers
por: Ruan, Jian, et al.
Publicado: (2023)

Treatment of solid tumors with immunotoxins
por: Messmer, Davorka, et al.
Publicado: (2005)

Bouganin, an Attractive Weapon for Immunotoxins
por: Bortolotti, Massimo, et al.
Publicado: (2018)

Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands
por: Versteven, Maarten, et al.
Publicado: (2022)

Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin
por: Jiemy, William F., et al.
Publicado: (2020)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins
Publicado: (1982)

Cytotoxins and immunotoxins for cancer therapy : clinical applications /
Publicado: (2005)

Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors
por: Pilbeam, Kristy, et al.
Publicado: (2017)

Immunotoxins: From Design to Clinical Application
por: Kreitman, Robert J., et al.
Publicado: (2021)

Toxin and Immunotoxin Based Therapeutic Approaches
por: Bortolotti, Massimo, et al.
Publicado: (2022)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
por: Yim, Nam-Hui, et al.
Publicado: (2020)

Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
por: Goto, Hiroyuki, et al.
Publicado: (2021)

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis
por: Deepak, H. B., et al.
Publicado: (2022)

B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease.
por: Vooijs, W. C., et al.
Publicado: (1997)

In vivo quantification of programmed death-ligand-1 expression heterogeneity in tumors using fluorescence lifetime imaging
por: Pal, Rahul, et al.
Publicado: (2023)

Programmed death-ligand 1 expression in rectal cancer
por: Jomrich, G., et al.
Publicado: (2016)

Status of programmed death-ligand 1 expression in sarcomas
por: Park, Hyung Kyu, et al.
Publicado: (2018)

Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results
por: Mason-Osann, Emily, et al.
Publicado: (2015)

Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
por: Zhang, Yan, et al.
Publicado: (2011)

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
por: Liu, Xiaojun, et al.
Publicado: (2016)

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
por: Liu, Qiang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_02kk65kvvl0ej58ipjrd1uooli